Log In
Print
BCIQ
Print
Print this Print this
 

TO-2070

  Manage Alerts
Collapse Summary General Information
Company Shin Nippon Biomedical Laboratories Ltd.
DescriptionIntranasal formulation of dihydroergotamine (DHE)
Molecular Target Serotonin (5-HT) receptor
Mechanism of ActionSerotonin (5-HT) receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationMigraine
Indication DetailsTreat acute migraine
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$375.8M

$1.0M

$41.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today